Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 2/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 10/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 8/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | IDH1 | O75874 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4610330 | 0.91 | GRIN2B (0.36) | GRM5GRIN2BGRIN1NPC1RAB9A | |
| SCHEMBL4590755 | 0.90 | GRM2 (0.44) | GRM2ESR1ESR2NPC1TP53 | |
| SCHEMBL4590958 | 0.87 | GRM2 (0.47) | GRM2ESR1ESR2MCHR1 | |
| SCHEMBL4591304 | 0.84 | KDM1A (0.37) | GRM2ALDH1A1ESR1ESR2NPC1 | |
| SCHEMBL4590528 | 0.83 | NPC1 (0.46) | ESR1ESR2NPC1RAB9AMCHR1 | |
| SCHEMBL4591441 | 0.83 | NPC1 (0.40) | ALDH1A1ESR1ESR2NPC1RAB9A | |
| SCHEMBL4590135 | 0.82 | ESR1 (0.39) | ESR1ESR2NPC1RAB9AMCHR1 | |
| SCHEMBL4590764 | 0.81 | HPGD (0.45) | — | |
| SCHEMBL4590894 | 0.81 | MEN1 (0.44) | ALDH1A1ESR1ESR2RAB9A | |
| SCHEMBL4591482 | 0.80 | KDM1A (0.41) | ALDH1A1ESR1ESR2MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518976-B2 | e.g. 1-(3-(6-(2-fluorophenyl)pyridin-3-yl)propyl)-1H-pyridin-2-one; endothelial nitric oxide NO synthase inhibitor; antiinflammatory, hypotensive agent; atherosclerosis, thrombosis, coronary artery disease, and cardiac insufficiency | SANOFI (FR) | 2013-08-27 | — | — | US | claimed |
| EP-1899321-B1 | HETEROARYL-SUBSTITUTED AMIDES COMPRISING A SATURATED LINKER GROUP, AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2011-12-28 | — | — | EP | claimed |
| US-20080171739-A1 | Heteroaryl-Substituted Amides Comprising A Saturated Linker Group, And Their Use As Pharmaceuticals | SANOFI-AVENTIS (FR) | 2008-07-17 | — | — | US | claimed |
| EP-1899321-A1 | HETEROARYL-SUBSTITUTED AMIDES COMPRISING A SATURATED LINKER GROUP, AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2008-03-19 | — | — | EP | claimed |
| WO-2007000246-A1 | HETEROARYL-SUBSTITUTED AMIDES COMPRISING A SATURATED LINKER GROUP, AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-01-04 | — | — | WO | claimed |
| US-8518976-B2 | e.g. 1-(3-(6-(2-fluorophenyl)pyridin-3-yl)propyl)-1H-pyridin-2-one; endothelial nitric oxide NO synthase inhibitor; antiinflammatory, hypotensive agent; atherosclerosis, thrombosis, coronary artery disease, and cardiac insufficiency | SANOFI (FR) | 2013-08-27 | — | — | US | disclosed |
| EP-1899321-B1 | HETEROARYL-SUBSTITUTED AMIDES COMPRISING A SATURATED LINKER GROUP, AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2011-12-28 | — | — | EP | disclosed |
| US-20080171739-A1 | Heteroaryl-Substituted Amides Comprising A Saturated Linker Group, And Their Use As Pharmaceuticals | SANOFI-AVENTIS (FR) | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171739-A1 | Heteroaryl-Substituted Amides Comprising A Saturated Linker Group, And Their Use As Pharmaceuticals | TBXAS1, PTGIS, NOS2 | GRM2 2000/4885GRM5 1685/4885GRIN2B 1876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.